Cybin Inc (CYBN) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.117x

Based on the latest financial reports, Cybin Inc (CYBN) has a cash flow conversion efficiency ratio of -0.117x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-31.95 Million ≈ $-23.11 Million USD) by net assets (CA$273.93 Million ≈ $198.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CYBN defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Cybin Inc - Cash Flow Conversion Efficiency Trend (2020–2025)

This chart illustrates how Cybin Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Cybin Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cybin Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Pekat Group Bhd
KLSE:0233
0.033x
Hubtown Limited
NSE:HUBTOWN
0.035x
Korea Environment Technology Co. LTD
KQ:029960
0.041x
Guangxi Hechi Chemical Co Ltd
SHE:000953
0.071x
Materialise NV
F:06MA
0.041x
Promotora Ambiental S.A.B. de C.V
MX:PASAB
0.211x
Cohen Circle Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CCIR
-0.003x
Brompton Split Banc Corp
TO:SBC
0.008x

Annual Cash Flow Conversion Efficiency for Cybin Inc (2020–2025)

The table below shows the annual cash flow conversion efficiency of Cybin Inc from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see CYBN company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 CA$237.20 Million
≈ $171.59 Million
CA$-101.30 Million
≈ $-73.28 Million
-0.427x -80.93%
2024-03-31 CA$291.93 Million
≈ $211.18 Million
CA$-68.91 Million
≈ $-49.85 Million
-0.236x +76.00%
2023-03-31 CA$48.23 Million
≈ $34.89 Million
CA$-47.43 Million
≈ $-34.31 Million
-0.983x -65.65%
2022-03-31 CA$76.16 Million
≈ $55.09 Million
CA$-45.21 Million
≈ $-32.70 Million
-0.594x -168.68%
2021-03-31 CA$86.12 Million
≈ $62.30 Million
CA$-19.03 Million
≈ $-13.76 Million
-0.221x +76.90%
2020-03-31 CA$1.45 Million
≈ $1.05 Million
CA$-1.38 Million
≈ $-1.00 Million
-0.956x --

About Cybin Inc

NEO:CYBN Canada Biotechnology
Market Cap
$301.37 Million
CA$416.62 Million CAD
Market Cap Rank
#14911 Global
#444 in Canada
Share Price
CA$8.35
Change (1 day)
-27.89%
52-Week Range
CA$7.70 - CA$11.99
All Time High
CA$150.86
About

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anx… Read more